eMedicine Specialties > Nephrology > Acid-Base, Fluid, and Electrolyte Disorders

Hyperphosphatemia: Multimedia

Author: Eleanor Lederer, MD, Consulting Staff, Louisville VA Hospital; Professor of Medicine; Interim Chief of Nephrology; Director of Nephrology Training Program; Director, Metabolic Stone Clinic; Director of Outpatient Clinics, Kidney Disease Program, University of Louisville School of Medicine
Coauthor(s): Rosemary Ouseph, MD, Professor of Medicine, Director of Kidney Transplant, University of Louisville School of Medicine; Vibha Nayak, MD, Fellow in Nephrology, Department of Internal Medicine, University of Louisville School of Medicine
Contributor Information and Disclosures

Updated: Aug 6, 2009

Multimedia

Approximately 60-70% of dietary phosphate, 1000-1...
(Enlarge Image)
Media file 1: Approximately 60-70% of dietary phosphate, 1000-1500 mg/d, is absorbed in the small intestine. Although vitamin D can enhance the absorption, especially under conditions of dietary phosphate depletion, intestinal phosphate absorption is generally unregulated. Specifically, high serum phosphate and high dietary phosphate intake do not significantly impair intestinal uptake. The movement of phosphate in and out of bone, the reservoir containing most of the total body phosphate, is generally balanced. Renal excretion of excess dietary phosphate intake ensures maintenance of phosphate homeostasis, maintaining serum phosphate at a level of approximately 4.5 mg/dL in the serum.
[ CLOSE WINDOW ]
Approximately 60-70% of dietary phosphate, 1000-1...

Approximately 60-70% of dietary phosphate, 1000-1500 mg/d, is absorbed in the small intestine. Although vitamin D can enhance the absorption, especially under conditions of dietary phosphate depletion, intestinal phosphate absorption is generally unregulated. Specifically, high serum phosphate and high dietary phosphate intake do not significantly impair intestinal uptake. The movement of phosphate in and out of bone, the reservoir containing most of the total body phosphate, is generally balanced. Renal excretion of excess dietary phosphate intake ensures maintenance of phosphate homeostasis, maintaining serum phosphate at a level of approximately 4.5 mg/dL in the serum.

The vast majority of filtered phosphate is reabso...
(Enlarge Image)
Media file 2: The vast majority of filtered phosphate is reabsorbed by type 2a sodium phosphate cotransporters located on the apical membrane of the renal proximal tubule. The expression of these cotransporters is increased by low dietary phosphate intake and several growth factors to enhance phosphate absorption. The expression is decreased by high dietary phosphate intake, parathyroid hormone, and dopamine. Phosphate absorption in the remainder of the nephron is generally mediated by type 1 or 3 sodium phosphate cotransporters. No direct evidence related to regulation of these transporters in renal cells under physiologic conditions has been found. The absorption in the proximal tubule is regulated such that the final excretion matches the dietary excess in order to maintain homeostasis.
[ CLOSE WINDOW ]
The vast majority of filtered phosphate is reabso...

The vast majority of filtered phosphate is reabsorbed by type 2a sodium phosphate cotransporters located on the apical membrane of the renal proximal tubule. The expression of these cotransporters is increased by low dietary phosphate intake and several growth factors to enhance phosphate absorption. The expression is decreased by high dietary phosphate intake, parathyroid hormone, and dopamine. Phosphate absorption in the remainder of the nephron is generally mediated by type 1 or 3 sodium phosphate cotransporters. No direct evidence related to regulation of these transporters in renal cells under physiologic conditions has been found. The absorption in the proximal tubule is regulated such that the final excretion matches the dietary excess in order to maintain homeostasis.

Hyperphosphatemia inhibits 1-alpha hydroxylase in...
(Enlarge Image)
Media file 3: Hyperphosphatemia inhibits 1-alpha hydroxylase in the proximal tubule, thus inhibiting the conversion of 25-hydroxy vitamin D3 to the active metabolite, 1,25 dihydroxyvitamin D3. The decrease in active vitamin D production is somewhat offset by the ability of hyperphosphatemia to stimulate the secretion of parathyroid hormone (PTH), which will increase the activity of 1-alpha hydroxylase. The result is generally a neutral effect on intestinal phosphate absorption. Hyperphosphatemia-stimulated PTH secretion is mediated through an as yet unidentified pathway. With normal renal function, the transient increase in PTH and decrease in vitamin D serve to inhibit renal and intestinal absorption of phosphate, resulting in resolution of the hyperphosphatemia. In contrast, under conditions of renal failure, sustained hyperphosphatemia results in sustained hyperparathyroidism. The hyperparathyroidism enhances renal phosphate excretion but also enhances bone resorption, releasing more phosphate into the serum. As renal failure progresses and the ability of the kidney to excrete phosphate continues to diminish, the action of PTH on the bone can exacerbate the already present hyperphosphatemia.
[ CLOSE WINDOW ]
Hyperphosphatemia inhibits 1-alpha hydroxylase in...

Hyperphosphatemia inhibits 1-alpha hydroxylase in the proximal tubule, thus inhibiting the conversion of 25-hydroxy vitamin D3 to the active metabolite, 1,25 dihydroxyvitamin D3. The decrease in active vitamin D production is somewhat offset by the ability of hyperphosphatemia to stimulate the secretion of parathyroid hormone (PTH), which will increase the activity of 1-alpha hydroxylase. The result is generally a neutral effect on intestinal phosphate absorption. Hyperphosphatemia-stimulated PTH secretion is mediated through an as yet unidentified pathway. With normal renal function, the transient increase in PTH and decrease in vitamin D serve to inhibit renal and intestinal absorption of phosphate, resulting in resolution of the hyperphosphatemia. In contrast, under conditions of renal failure, sustained hyperphosphatemia results in sustained hyperparathyroidism. The hyperparathyroidism enhances renal phosphate excretion but also enhances bone resorption, releasing more phosphate into the serum. As renal failure progresses and the ability of the kidney to excrete phosphate continues to diminish, the action of PTH on the bone can exacerbate the already present hyperphosphatemia.

More on Hyperphosphatemia

Overview: Hyperphosphatemia
Differential Diagnoses & Workup: Hyperphosphatemia
Treatment & Medication: Hyperphosphatemia
Follow-up: Hyperphosphatemia
Multimedia: Hyperphosphatemia
References
Further Reading
[ CLOSE WINDOW ]

References

  1. Prie D, Huart V, Bakouh N, Planelles G, Dellis O, Gerard B, et al. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mujtations in the type 2a sodium-phosphate cotransporter. N Engl J Med. 2002;347:98991. [Medline].

  2. Segawa H, Onitsuka A, Kuwahata M, Hanabusa E, Furutani J, Kaneko I, et al. Type IIc sodium-dependent phosphate transporter regulates calcium metabolism. J Amn Soc Nephrol. 2009;20:104-113. [Medline].

  3. Collins JF, Bai L, Ghishan FK. The SLC20 family of proteins: dual functions as sodium-phosphate cotransporters and viral receptors. Pflugers Arch. 2004;447:647-652. [Medline].

  4. Nowik M, Picard N, Stange G, et al. Renal phosphaturia during metabolic acidosis revisited: molecular mechanisms for decreased renal phosphate reabsorption. Pflugers Arch. Nov 2008;457(2):539-49. [Medline].

  5. Virkki LV, Biber J, Murer H, Forster IC. Phosphate transporters: a tale of two solute carrier families. Am J Physiol Renal Physiol. 2007;293:F643-F654. [Medline].

  6. Shaikh A, Berndt T, Kumar R. Regulation of phospahte homeostasis by the phosphatonins and other novel mediators. Pediatr Nephrol. 2008;23:1203-1210. [Medline].

  7. Mirams M, Robinson BG, Mason RS, Nelson AE. Bone as a source of FGF23: regulation by phosphate?. Bone. Nov 2004;35(5):1192-9. [Medline].

  8. Liu S, Zhou J, Tang W, et al. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab. Jul 2006;291(1):E38-49. [Medline].

  9. Razzaque MS. FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player. Am J Physiol Renal Physiol. 2009;296:F470-F476. [Medline].

  10. Pande S, Ritter CS, Rothstein M, et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol. 2006;104(1):p23-32. [Medline].

  11. Nishida Y, Taketani Y, Yamanaka-Okumura H, et al. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int. Dec 2006;70(12):2141-7. [Medline].

  12. Prie D, Beck L, Urena P, Friedlander G. Recent findings in phosphate homeostasis. Curr Opin Nephrol Hypertens. 2005;14:318-324. [Medline].

  13. Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin INvest. 2007;117:2684-2691. [Medline].

  14. Ichikawa S, Sorenson AH, Austin AM, Mackenzie DS, Fritz TA, Moh A, et al. Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression. Endocrinology. 2009;150:2543-2550. [Medline].

  15. Lammoglia JJ, Mericq V. Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer. Horm Res. 2009;71:178-184. [Medline].

  16. Barbieri AM, Filopanti M, Bua G, Beck-Peccoz P. Two novel nonsense mutations in GALNT3 gene are responsible for familial tumoral calcinosis. J Hum Genet. 2007;52:464-468. [Medline].

  17. Beloosesky Y, Grinblat J, Weiss A, Grosman B, Gafter U, Chagnac A. Electrolyte disorders following oral sodium phospahte administration for bowel cleansing in elderly patients. Arch Intern Med. 2003;163:803-808. [Medline].

  18. Gumurdulu Y, Serin E, Ozer B, Gokcel A, Boyacioglu S. Age as a predictor of hyperphosphatemia after oral phosphosoda administration for colon preparation. J Gastroenterol Hepatol. 2004;19:68-72. [Medline].

  19. Markowitz GS, Stokes MB, Radhakrishnan J, D'Agati VD. Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. J Am Soc Nephrol. 2005;16:3389-3396. [Medline].

  20. Markowitz GS, Nasr SH, Klein P, Anderson H, Stack JI, Alterman L, et al. Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing. Hum Pathol. 2004;35:675-684. [Medline].

  21. Connolly GM, Cunningham R, McNamee PT, Young IS, Maxwell AP. Elevated serum phosphate predicts mortality in renal transplant recipients. Transplantation. 2009;87:1041-1044. [Medline].

  22. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52:519-530. [Medline].

  23. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney International. 2008;74:148-157. [Medline].

  24. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G, Cholesterol and Recurrent Events Trial Investigators. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005;112:2627-2633. [Medline].

  25. Cannata-Andia JB, Naves-Diaz M. Phosphorus and Survival: Key Questions That Need Answers. J Am Soc Nephrol. 2009;20:234-236. [Medline].

  26. Sabbagh Y, Carpenter TO, Demay MB. Hypophospphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. Proc Natl Acad Sci USA. 2005;102:9637-9642. [Medline].

  27. Shuto E, Taketani Y, Tanaka R, Harada N, Isshiki M, Sato M, et al. Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol. 2009;20:1504-1512. [Medline].

  28. Ball CL, Tobler K, Ross BC, Connors MR, Lyon ME. Spurious hyperphosphatemia due to sample contamination with heparinized saline from an indwelling catheter. Clin Chem Lab Med. Jan 2004;42(1):107-8. [Medline].

  29. Cachat F, Bardy D, Durussel C, Di Paolo E. Spurious hyperphosphatemia in a patient with alteplase-locked central venous catheter. Pediatr Nephrol. Feb 2006;21(2):301-2. [Medline].

  30. Marcu CB, Hotchkiss M. Pseudohyperphosphatemia in a patient with multiple myeloma. Conn Med. Feb 2004;68(2):71-2. [Medline].

  31. Larner AJ. Pseudohyperphosphatemia. Clin Biochem. Aug 1995;28(4):391-3. [Medline].

  32. Leehey DJ, Daugirdas JT, Ing TS, Reid RW. Spurious hyperphosphatemia due to hyperlipidemia. Arch Intern Med. Apr 1985;145(4):743-4. [Medline].

  33. Frazao JM, Adragao T. Treatment of hyperphosphatemia with sevelamer hydrochloride in dialoysis patients: effects on vascular calcification, bone and a close look into the survival data. Kidney Int Suppl. 2008;111:S38-S43. [Medline].

  34. Sprague SM. A comparative review of the efficacy and safety of established phospahte binders: calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin. 2007;23:3167-3175. [Medline].

  35. Marangon N, Lindholm B, Stenvinkel P. Nonphosphate-binding effects of sevelamer--are they of clinical relevance?. Semin Dial. 2008;21:385-389. [Medline].

  36. Takei T, Otsubo S, Uchida K, Matsugami K, Mimuro T, Kabaya T, et al. Effects of sevelamer on the progression of vacular calcification in pateints on chronic hemodialysis. Nephron Clin Pract. 2008;108:c278-283. [Medline].

  37. Connor A. Novel therapeutic agents and strategies for the management of chronic kidney disease mineral and bone disorder. Postgrad Med J. 2009;85:274-279.

  38. Barreto DV, Barreto FdeC, de Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, et al. Phosphate binder impact on bone remodeling and coronary calcification -- results from the BRIC study. Nephron Clin Pract. 2008;110:c278-c283. [Medline].

  39. Ahmed S, O''Neill KD, Hood AF, et al. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis. Jun 2001;37(6):1267-76. [Medline].

  40. Bastepe M, Juppner H. Pseudohypoparathyroidism. New insights into an old disease. Endocrinol Metab Clin North Am. Sep 2000;29(3):569-89. [Medline].

  41. Berndt T, Craig TA, Bowe AE, et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest. Sep 2003;112(5):785-94. [Medline].

  42. Biarent D, Brumagne C, Steppe M, Bouton JM. Acute phosphate intoxication in seven infants under parenteral nutrition. JPEN J Parenter Enteral Nutr. Nov-Dec 1992;16(6):558-60. [Medline].

  43. Blay P, Fernandez-Martinez JM, Diaz-Lopez B. Vertebral involvement in hyperphosphatemic tumoral calcinosis. Bone. Mar 2001;28(3):316-8. [Medline].

  44. Block GA. Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis). Curr Opin Nephrol Hypertens. Nov 2001;10(6):741-7. [Medline].

  45. Burke SK, Amin NS, Incerti C, et al. Sevelamer hydrochloride (Renagel), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers. J Clin Pharmacol. Feb 2001;41(2):199-205. [Medline].

  46. Carpenter TO. Oncogenic osteomalacia--a complex dance of factors. N Engl J Med. Apr 24 2003;348(17):1705-8. [Medline].

  47. Carvalho AB, Lobao RR, Cuppari L, et al. Does hypophosphataemia induce hypoparathyroidism in pre-dialysis patients?. Nephrol Dial Transplant. 1998;13 Suppl 3:12-4. [Medline].

  48. Chen NX, Moe SM. Vascular calcification in chronic kidney disease. Semin Nephrol. Jan 2004;24(1):61-8. [Medline].

  49. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant. Dec 1999;14(12):2907-14. [Medline].

  50. Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. Jul 2002;62(1):245-52. [Medline].

  51. Connor A. Novel therapeutic agents and strategies for the management of chronic kidney disease mineral and bone disorder. Postgrad Med J. 2009;85:274-278. [Medline].

  52. Cozzolino M, Dusso AS, Slatopolsky E. Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. J Am Soc Nephrol. 2001;12(11):2511-6. [Medline].

  53. Davies MR, Hruska KA. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int. 2001;60(2):472-9. [Medline].

  54. DiMeglio LA, White KE, Econs MJ. Disorders of phosphate metabolism. Endocrinol Metab Clin North Am. Sep 2000;29(3):591-609. [Medline].

  55. Drezner MK. PHEX gene and hypophosphatemia. Kidney Int. Jan 2000;57(1):9-18. [Medline].

  56. Fine A, Patterson J. Severe hyperphosphatemia following phosphate administration for bowel preparation in patients with renal failure: two cases and a review of the literature. Am J Kidney Dis. Jan 1997;29(1):103-5. [Medline].

  57. Finn WF, Joy MS, Hladik G; Lanthanum Study Group. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol. Sep 2004;62(3):193-201. [Medline].

  58. Fiorino AS. Hypercalcemia and alkalosis due to the milk-alkali syndrome: a case report and review. Yale J Biol Med. Nov-Dec 1996;69(6):517-23. [Medline].

  59. Fournier A, Oprisiu R, Albu AT, et al. The crossover comparative trial of calcium acetate versus sevelamer hydrochloride (Renagel) as phosphate binders in dialysis patients. Am J Kidney Dis. Jun 2000;35(6):1248-50. [Medline].

  60. Gallieni M, Cozzolino M, Carpani P, et al. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients. J Nephrol. May-Jun 2001;14(3):176-83. [Medline].

  61. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. Oct 2001;12(10):2131-8. [Medline].

  62. Garfield N, Karaplis AC. Genetics and animal models of hypoparathyroidism. Trends Endocrinol Metab. Sep 2001;12(7):288-94. [Medline].

  63. Goldsmith D, Ritz E, Covic A. Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease?. Kidney Int. 66(4):1315-33. [Medline].

  64. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. May 18 2000;342(20):1478-83. [Medline].

  65. Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, Smith K, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009;20:386-396. [Medline].

  66. Ishibashi K, Imai M. Prospect of a stanniocalcin endocrine/paracrine system in mammals. Am J Physiol Renal Physiol. Mar 2002;282(3):F367-75. [Medline].

  67. Jeha S. Tumor lysis syndrome. Semin Hematol. 2001;38(4 Suppl 10):4-8. [Medline].

  68. Jonsson KB, Mannstadt M, Miyauchi A, et al. Extracts from tumors causing oncogenic osteomalacia inhibit phosphate uptake in opossum kidney cells. J Endocrinol. Jun 2001;169(3):613-20. [Medline].

  69. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. Apr 24 2003;348(17):1656-63. [Medline].

  70. Joy MS, Finn WF, LAM-302 Study Group. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 42(1):96-107. [Medline].

  71. Kalemkerian GP, Darwish B, Varterasian ML. Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med. Nov 1997;103(5):363-7. [Medline].

  72. Kirschbaum B. The acidosis of exogenous phosphate intoxication. Arch Intern Med. Feb 23 1998;158(4):405-8. [Medline].

  73. Kumar R. New insights into phosphate homeostasis: fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia. Curr Opin Nephrol Hypertens. Sep 2002;11(5):547-53. [Medline].

  74. Kumar R. Tumor-induced osteomalacia and the regulation of phosphate homeostasis. Bone. Sep 2000;27(3):333-8. [Medline].

  75. Lania A, Mantovani G, Spada A. G protein mutations in endocrine diseases. Eur J Endocrinol. Nov 2001;145(5):543-59. [Medline].

  76. Larsson T, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. Dec 2003;64(6):2272-9. [Medline].

  77. Lee KW, Cohen KL, Walters JB, Federman DG. Iatrogenic vitamin D intoxication: report of a case and review of vitamin D physiology. Conn Med. Jul 1999;63(7):399-403. [Medline].

  78. Levi M. Novel NaPi-2c mutations that cause mistargeting of NaPi-2c protein and uncoupling of Na-Pi cotransport cause HHRH. Am J Physiol Renal Physiol. 2008;295:F369-370. [Medline].

  79. Levin NW, Hoenich NA. Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patients. Curr Opin Nephrol Hypertens. Sep 2001;10(5):563-8. [Medline].

  80. Levine MA. Clinical spectrum and pathogenesis of pseudohypoparathyroidism. Rev Endocr Metab Disord. Nov 2000;1(4):265-74. [Medline].

  81. Liu YL, Lin HH, Yu CC, Kuo HL, Yang YF, Chou CY. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients. Ren Fail. 2006;28(8):701-7. [Medline].

  82. Llach F. Hyperphosphatemia in end-stage renal disease patients: pathophysiological consequences. Kidney Int Suppl. Dec 1999;73:S31-7. [Medline].

  83. Locatelli F, Cannata-Andia JB, Drueke TB, et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant. 2002;17(5):723-31. [Medline].

  84. Loghman-Adham M. Phosphate binders for control of phosphate retention in chronic renal failure. Pediatr Nephrol. Oct 1999;13(8):701-8. [Medline].

  85. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 18(9):1731-40. [Medline].

  86. Malluche HH, Monier-Faugere MC. Hyperphosphatemia: pharmacologic intervention yesterday, today and tomorrow. Clin Nephrol. Oct 2000;54(4):309-17. [Medline].

  87. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med. Dec 21 2000;343(25):1863-75. [Medline].

  88. Masi L, Gozzini A, Franchi A, Campanacci D, Amedei A, Falchetti A, et al. A novel recessive mutation of fibroblast growth factor-23 in tumoral calcinosis. J Bone Joint Surg Am. 2009;91:1190-8. [Medline].

  89. Mauro LS, Kuhl DA, Kirchhoff JR, et al. Impact of oral bases on aluminum absorption. Am J Ther. Jan-Feb 2001;8(1):21-5. [Medline].

  90. Moe SM, O''Neill KD, Duan D, et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int. Feb 2002;61(2):638-47. [Medline].

  91. Narchi H. Hyperostosis with hyperphosphatemia: evidence of familial occurrence and association with tumoral calcinosis. Pediatrics. May 1997;99(5):745-8. [Medline].

  92. Nelson AE, Bligh RC, Mirams M, et al. Clinical case seminar: Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab. Sep 2003;88(9):4088-94. [Medline].

  93. Nelson AE, Hogan JJ, Holm IA, et al. Phosphate wasting in oncogenic osteomalacia: PHEX is normal and the tumor-derived factor has unique properties. Bone. Apr 2001;28(4):430-9. [Medline].

  94. Payne RB. Renal tubular reabsorption of phosphate (TmP/GFR): indications and interpretation. Ann Clin Biochem. Mar 1998;35 ( Pt 2):201-6. [Medline].

  95. Quarles LD. Evidence for a bone-kidney axis regulating phosphate homeostasis. J Clin Invest. Sep 2003;112(5):642-6. [Medline].

  96. Quarles LD. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab. Jul 2003;285(1):E1-9. [Medline].

  97. Raggi P. Effects of excess calcium load on the cardiovascular system measured with electron beam tomography in end-stage renal disease. Nephrol Dial Transplant. 2002;17(2):332-5. [Medline].

  98. Ribeiro S, Ramos A, Brandao A, et al. Cardiac valve calcification in haemodialysis patients: role of calcium- phosphate metabolism. Nephrol Dial Transplant. Aug 1998;13(8):2037-40. [Medline].

  99. Rowe PS, Kumagai Y, Gutierrez G, et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone. Feb 2004;34(2):303-19. [Medline].

  100. Savaci N, Avunduk MC, Tosun Z, Hosnuter M. Hyperphosphatemic tumoral calcinosis. Plast Reconstr Surg. Jan 2000;105(1):162-5. [Medline].

  101. Savica V, Calo LA, Monardo P, Davis PA, Granata A, Santoro D, et al. Salivary phosphate-binding chewing gum reduces hyperphospahtemia in dialysis pateints. J Am Soc Nephrol. 2009;20:639-644. [Medline].

  102. Schiavi SC, Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int. Jan 2004;65(1):1-14. [Medline].

  103. Schoenhagen P, Tuzcu EM. Coronary artery calcification and end-stage renal disease: vascular biology and clinical implications. Cleve Clin J Med. 2002;69 Suppl 3:S12-20. [Medline].

  104. Segawa H, Kawakami E, Kaneko I, et al. Effect of hydrolysis-resistant FGF23-R179Q on dietary phosphate regulation of the renal type-II Na/Pi transporter. Pflugers Arch. Aug 2003;446(5):585-92. [Medline].

  105. Shaoul R, Wolff R, Seligmann H, et al. Symptoms of hyperphosphatemia, hypocalcemia, and hypomagnesemia in an adolescent after the oral administration of sodium phosphate in preparation for a colonoscopy. Gastrointest Endosc. May 2001;53(6):650-2. [Medline].

  106. Shioi A, Taniwaki H, Jono S, et al. Monckeberg''s medial sclerosis and inorganic phosphate in uremia. Am J Kidney Dis. Oct 2001;38(4 Suppl 1):S47-9. [Medline].

  107. Slatopolsky E, Brown A, Dusso A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis. 2001;37(1 Suppl 2):S54-7. [Medline].

  108. Uhlig K, Sarnak MJ, Singh AK. New approaches to the treatment of calcium and phosphorus abnormalities in patients on hemodialysis. Curr Opin Nephrol Hypertens. Nov 2001;10(6):793-8. [Medline].

  109. Weinstein LS, Yu S, Warner DR, Liu J. Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev. Oct 2001;22(5):675-705. [Medline].

  110. White KE, Carn G, Lorenz-Depiereux B, et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. Dec 2001;60(6):2079-86. [Medline].

  111. Yasuda T, Niimi H. Hypoparathyroidism and pseudohypoparathyroidism. Acta Paediatr Jpn. Aug 1997;39(4):485-90. [Medline].

[ CLOSE WINDOW ]

Further Reading

Related eMedicine topics:
Chronic Renal Failure
Hyperphosphatemia [Emergency Medicine]
Hypocalcemia [Emergency Medicine]
Hypocalcemia [Nephrology]
Hypocalcemia [Pediatrics: General Medicine]
Hypophosphatemia [Emergency Medicine]
Hypophosphatemia [Nephrology]
Pseudohypoparathyroidism

Clinical guidelines:
K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. National Kidney Foundation - Disease Specific Society.  2005 Oct.  121 pages.  NGC:005108

Clinical trials:
Efficacy of SBR759 in Lowering Serum Phosphate levels in Chronic Kidney Disease Patients on Hemodialysis

Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate

[ CLOSE WINDOW ]

Keywords

hyperphosphatemia, phosphate calcium, hypocalcemia, pseudohypoparathyroidism, phosphate levels, phosphate level, high phosphate, phosphate homeostasis, phosphate binders, sodium-phosphate cotransporters, parathyroid hormone, PTH, dopamine, dietary phosphate, renal proximal tubule phosphate reabsorption, pseudohypoparathyroidism, hypomagnesemia, rhabdomyolysis, tumor lysis, renal failure, vascular calcifications, calciphylaxis, chronic renal failure, CRF, acute renal failure, kidney failure, renal disease, kidney disease, excessive phosphate intake, excessive phosphate ingestion, decreased phosphate excretion, vitamin D intoxication, hypoparathyroidism, pseudo-hypoparathyroidism

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Eleanor Lederer, MD, Consulting Staff, Louisville VA Hospital; Professor of Medicine; Interim Chief of Nephrology; Director of Nephrology Training Program; Director, Metabolic Stone Clinic; Director of Outpatient Clinics, Kidney Disease Program, University of Louisville School of Medicine
Eleanor Lederer, MD is a member of the following medical societies: American Association for the Advancement of Science, American Federation for Medical Research, American Society for Biochemistry and Molecular Biology, American Society for Bone and Mineral Research, American Society of Nephrology, American Society of Transplantation, International Society of Nephrology, Kentucky Medical Association, National Kidney Foundation, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Coauthor(s)

Rosemary Ouseph, MD, Professor of Medicine, Director of Kidney Transplant, University of Louisville School of Medicine
Rosemary Ouseph, MD is a member of the following medical societies: American Society for Bone and Mineral Research, American Society of Nephrology, and American Society of Transplant Surgeons
Disclosure: Nothing to disclose.

Vibha Nayak, MD, Fellow in Nephrology, Department of Internal Medicine, University of Louisville School of Medicine
Disclosure: Nothing to disclose.

Medical Editor

Anil Kumar Mandal, MD, Clinical Professor, Department of Internal Medicine, Division of Nephrology, University of Florida School of Medicine
Anil Kumar Mandal, MD is a member of the following medical societies: American College of Clinical Pharmacology, American College of Physicians, American Society of Nephrology, and Central Society for Clinical Research
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Christie P Thomas, MBBS, FRCP, FASN, FAHA, Professor, Department of Internal Medicine, Division of Nephrology, University of Iowa Hospitals and Clinics; Director of Transplantation Services, Veterans Affairs Medical Center
Christie P Thomas, MBBS, FRCP, FASN, FAHA is a member of the following medical societies: American College of Physicians, American Federation for Medical Research, American Heart Association, American Society of Nephrology, American Society of Transplantation, American Thoracic Society, International Society of Nephrology, and Royal College of Physicians
Disclosure: Genzyme Grant/research funds Other

CME Editor

Rebecca J Schmidt, DO, FACP, FASN, Professor of Medicine, Section Chief, Department of Medicine, Section of Nephrology, West Virginia University School of Medicine
Rebecca J Schmidt, DO, FACP, FASN is a member of the following medical societies: American College of Osteopathic Internists, American College of Physicians, American Medical Association, American Society of Nephrology, International Society of Nephrology, National Kidney Foundation, Renal Physicians Association, and West Virginia State Medical Association
Disclosure: Abbott Grant/research funds Speaking and teaching; Genzyme Honoraria Consulting; Amgen Honoraria Speaking and teaching; Ortho Biotech Honoraria Speaking and teaching

Chief Editor

Vecihi Batuman, MD, FACP, FASN, Professor of Medicine, Section of Nephrology-Hypertension, Tulane University School of Medicine; Chief, Medicine Service, Southeast Louisiana Veterans Health Care System
Vecihi Batuman, MD, FACP, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, and International Society of Nephrology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.